首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Epidemiological and Entomological Evaluations after Six Years or More of Mass Drug Administration for Lymphatic Filariasis Elimination in Nigeria
【2h】

Epidemiological and Entomological Evaluations after Six Years or More of Mass Drug Administration for Lymphatic Filariasis Elimination in Nigeria

机译:尼日利亚六年以上的消除淋巴丝虫病的大规模药物管理后的流行病学和昆虫学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area (LGA) prevalence of 23% (range 4–62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by community drug distributors over the intervention period. Reported treatment coverage for each round was ≥85% of the treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage (72.2%; 95% CI 65.5–79.0%). To determine impact on transmission, we monitored three LF infection parameters (microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in 2009, when SVs had been treated for 7–10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to 0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia ≥1% and/or L3 stages in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of >25%. Longer or additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for ‘hot spots’ where transmission is ongoing.
机译:中断淋巴丝虫病(LF)传播的当前策略是,在覆盖率良好的情况下,每年进行6年或更长时间的大规模药物管理(MDA)。我们描述了我们在尼日利亚中部的高原地区和纳萨拉瓦州提供依维菌素和阿苯达唑的MDA组合的程序设计经验,那里的LF是由按蚊碱传播的Wuchereria bancrofti引起的。使用快速血液抗原检测测试的基线LF定位显示平均地方政府区域(LGA)患病率为23%(范围4–62%)。 MDA于2000年启动,到2003年已扩大到两个州所有30个LGA的全部地理覆盖范围;在干预期间,社区药物经销商提供了超过2600万种直接观察到的累计治疗方法。尽管2003年基于人群的覆盖率调查显示覆盖率较低(72.2%; 95%CI 65.5-79.0%),但报告的每轮治疗覆盖率是370万符合治疗条件的人口的≥85%。为了确定对传播的影响,我们连续监测了10个前哨村庄(SV)的三个LF感染参数(微丝虫病,抗原血症和蚊子感染)。上一次监测是在2009年进行的,当时对SV进行了7-10年的治疗。 2009年微丝虫病较基线下降了83%(从4.9%降至0.8%);抗原血症增加了67%(从21.6%降至7.2%);蚊子感染率(所有幼虫阶段)提高了86%(从3.1%降至0.4%);蚊子感染率(L3级)为76%(从1.3%降至0.3%)。所有变化均具有统计学意义。结果表明,根据2009年在蚊子中发现的微丝虫病≥1%和/或L3阶段,LF传播在10个SV中有5个被中断。持续传播的5个SV中有4个的基线抗原血症患病率> 25%。对于传播正在进行的“热点”,应考虑采用更长或更长时间的干预措施(例如,更频繁的MDA治疗,杀虫床网)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号